Treprostinil (Tyvaso)
Small molecule
Evidence outlook
Approved: Pulmonary Arterial Hypertension, Pulmonary Hypertension Associated with Interstitial Lung Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Idiopathic Pulmonary Fibrosis · Phase 3 · under FDA review
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02630316 NCT02630316 · Pulmonary Hypertension Associated with Interstitial Lung Disease This was a randomized, quadruple-blind, placebo-controlled trial of 326 people, and inhaled treprostinil significantly improved six-minute walk distance at week 16 compared with placebo (p=0.0043). The trial reported a sample-size calculation for this endpoint and enrolled more participants than the calculation required. Registry: NCT02630316 | 2/3 | Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 (Baseline and Week 16) 2019-12-26 | Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results). | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Early phase / not applicable (1)
What this study did
Competitive landscape
Other IP receptor (prostacyclin pathway) drugs
Epoprostenol, Treprostinil (Orenitram), Treprostinil (Remodulin), Treprostinil (Tyvaso DPI), Treprostinil (Yutrepia, Liquidia) and 2 more. Compare all 8 IP receptor (prostacyclin pathway) drugs
This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Idiopathic Pulmonary Fibrosis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Treprostinil (Tyvaso): this drug | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Nerandomilast (Jascayd) | Approved | Small molecule | PDE4B | Reliable signal | NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5) NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88) | |
| Nintedanib (Ofev) | Approved | Small molecule | Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR) | Partial signal | NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results). NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results). | |
| Pirfenidone (Esbriet) | Approved | Small molecule | Pyridone | Reliable signal | NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results). | |
| Treprostinil (Tyvaso DPI) | Approved(overall) | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| HSK44459 | Phase 3 | Small molecule | PDE4B | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-722 | Phase 1(overall) | Small molecule | LPAR1 | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Pamrevlumab | Discontinued | Monoclonal antibody | CTGF | not yet graded | No reviewed efficacy summary in this indication | |
| Voxelotor (Oxbryta) | Discontinued | Small molecule | Hemoglobin S (HbS) | not yet graded | No reviewed efficacy summary in this indication | |
| Ziritaxestat | Discontinued | Small molecule | autotaxin (ENPP2) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Treprostinil (Tyvaso) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (5)
July 2027 (2)
November 2027 (1)
What to watch
2028 (1)
May 2028 (1)
What to watch
2029 (1)
December 2029 (1)
What to watch
2034 (1)
September 2034 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent